[go: up one dir, main page]

MA30090B1 - Utilisation d'un antagoniste de CB1 pour le traitement des effets secondaires et des symptômes négatifs de la schizophrénie - Google Patents

Utilisation d'un antagoniste de CB1 pour le traitement des effets secondaires et des symptômes négatifs de la schizophrénie

Info

Publication number
MA30090B1
MA30090B1 MA31081A MA31081A MA30090B1 MA 30090 B1 MA30090 B1 MA 30090B1 MA 31081 A MA31081 A MA 31081A MA 31081 A MA31081 A MA 31081A MA 30090 B1 MA30090 B1 MA 30090B1
Authority
MA
Morocco
Prior art keywords
schizophrenia
treatment
negative symptoms
antagonist
combination
Prior art date
Application number
MA31081A
Other languages
English (en)
Inventor
Mark Black
Beth Borowsky
Nancy Rogacki
Yaw Senyah
Rachel Stevens
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MA30090B1 publication Critical patent/MA30090B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention divulgue et revendique une méthode de traitement de déficits cognitifs chez un patient atteint de la schizophrénie par l'administration audit patient d'une quantité thérapeutiquement efficace d'un antagoniste du récepteur CB1 comme décrit dans la présente. Dans un autre aspect, cette invention divulgue et revendique également une combinaison d'un ou de plusieurs antagonistes du récepteur CB1 et d'un ou plusieurs agents antipsychotiques utiles dans le traitement de troubles psychiatriques. La combinaison de cette invention donne des résultats synergiques en ce que la combinaison améliore les symptômes positifs et négatifs de la schizophrénie, la prise de poids et la catalepsie.
MA31081A 2005-12-08 2008-06-26 Utilisation d'un antagoniste de CB1 pour le traitement des effets secondaires et des symptômes négatifs de la schizophrénie MA30090B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74843405P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
MA30090B1 true MA30090B1 (fr) 2008-12-01

Family

ID=37964962

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31081A MA30090B1 (fr) 2005-12-08 2008-06-26 Utilisation d'un antagoniste de CB1 pour le traitement des effets secondaires et des symptômes négatifs de la schizophrénie

Country Status (23)

Country Link
US (1) US20080221078A1 (fr)
EP (1) EP1962834A2 (fr)
JP (1) JP2009518423A (fr)
KR (1) KR20080073737A (fr)
CN (1) CN101321523A (fr)
AR (1) AR056846A1 (fr)
AU (1) AU2006321907A1 (fr)
BR (1) BRPI0619541A2 (fr)
CA (1) CA2632673A1 (fr)
CR (1) CR9957A (fr)
DO (1) DOP2006000273A (fr)
EC (1) ECSP088505A (fr)
IL (1) IL191888A0 (fr)
MA (1) MA30090B1 (fr)
NO (1) NO20082923L (fr)
PE (1) PE20071092A1 (fr)
RU (1) RU2008127491A (fr)
SV (1) SV2008002929A (fr)
TN (1) TNSN08205A1 (fr)
TW (1) TW200803839A (fr)
UY (1) UY29995A1 (fr)
WO (1) WO2007067617A2 (fr)
ZA (1) ZA200803924B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2007110449A1 (fr) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Composés de benzènesulfonamide et utilisation de ceux-ci
WO2007118854A1 (fr) 2006-04-13 2007-10-25 Euro-Celtique S.A. Composés à base de benzènesulfonamide et leur utilisation
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009040659A2 (fr) 2007-09-28 2009-04-02 Purdue Pharma L.P. Composés benzènesulfonamides et leurs utilisations
AU2008307572A1 (en) * 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
CA2709863A1 (fr) * 2007-12-18 2009-09-03 Sanofi-Aventis Derives d'azetidines, leur preparation et leur application en therapeutique
FR2925051B1 (fr) * 2007-12-18 2010-05-21 Sanofi Aventis Derives d'azetidines,leur preparation et leur application en therapeutique
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
WO2010079241A1 (fr) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CN107074841B (zh) 2014-08-11 2021-03-26 安吉恩生物医药公司 细胞色素p450抑制剂及其用途
CA2960275A1 (fr) * 2014-09-10 2016-03-17 Epizyme, Inc. Inhibiteurs de smyd
US10287282B2 (en) 2014-12-31 2019-05-14 Angion Biomedica Corp. Methods and agents for treating disease
BR112019003732A2 (pt) 2016-08-24 2020-02-18 Prilenia Therapeutics Development Ltd. Aplicação de pridopidina para tratamento de declínio funcional

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
CN1802351A (zh) * 2003-06-11 2006-07-12 麦克公司 被取代的3－烷基和3－链烯基氮杂环丁烷衍生物
RU2006110545A (ru) * 2003-09-02 2007-10-10 Зольвай Фармасьютикалз Гмбх (De) Новое медицинское применение избирательных антагонистов св1-рецептора
WO2006017892A1 (fr) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Procedes d'amelioration du fonctionnement cognitif
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique

Also Published As

Publication number Publication date
CR9957A (es) 2008-09-22
CN101321523A (zh) 2008-12-10
TW200803839A (en) 2008-01-16
AU2006321907A1 (en) 2007-06-14
RU2008127491A (ru) 2010-01-20
ZA200803924B (en) 2009-10-28
EP1962834A2 (fr) 2008-09-03
US20080221078A1 (en) 2008-09-11
SV2008002929A (es) 2009-12-02
JP2009518423A (ja) 2009-05-07
CA2632673A1 (fr) 2007-06-14
TNSN08205A1 (en) 2009-10-30
PE20071092A1 (es) 2007-12-10
AR056846A1 (es) 2007-10-24
DOP2006000273A (es) 2007-10-15
ECSP088505A (es) 2008-08-29
UY29995A1 (es) 2007-07-31
IL191888A0 (en) 2009-08-03
WO2007067617A2 (fr) 2007-06-14
KR20080073737A (ko) 2008-08-11
WO2007067617A3 (fr) 2007-11-01
BRPI0619541A2 (pt) 2011-10-04
NO20082923L (no) 2008-09-02

Similar Documents

Publication Publication Date Title
MA30090B1 (fr) Utilisation d'un antagoniste de CB1 pour le traitement des effets secondaires et des symptômes négatifs de la schizophrénie
ATE477252T1 (de) Substituierte diazepane als antagonisten an orexinrezeptoren
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
MA31451B1 (fr) Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
MA30900B1 (fr) Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
MA33538B1 (fr) Nouveaux antagonistes pyrimidine et triazine de l'hepcidine
UA100974C2 (ru) Соединения замещенных диазепанов как антагонисты орексиновых рецепторов
MA35419B1 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2007126935A3 (fr) Antagonistes des récepteurs de l'orexine sous forme de composés diazépane
MA34465B1 (fr) Inhibiteurs de tyrosine kinase de bruton
MA37525B1 (fr) Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine
EA200500172A1 (ru) Азабициклопроизводные в качестве антагонистов мускариновых рецепторов
EA200100936A1 (ru) Способы и композиции, использующие (+)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов
MA34939B1 (fr) Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation
EP2567701A3 (fr) Traitement de l'insuffisance cardiaque chez les animaux mammifères non humains par un antagoniste de l'aldostérone.
FR2856596B1 (fr) Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
EA201290764A1 (ru) Способы и композиции для улучшения когнитивной функции
MA32277B1 (fr) Derives de 2-phenyl-4- cyclopropyl-pyrimidine
MA29339B1 (fr) Derives du thiazole fondus ayant une affinite pour le recepteur de l'histamine h3
TW200733976A (en) Method for the treatment of cognitive dysfunction
NO20063856L (no) Behandling av psykoser med quetiapin-antipsykotiske midler
TNSN07355A1 (fr) Derives d'aryl-1,4-pyrazine substitues
MA56998B1 (fr) Traitement de symptômes induits par le cycle menstruel